Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Voyageur Pharmaceuticals ( (TSE:VM) ) has provided an announcement.
Voyageur Pharmaceuticals has launched a non-brokered private placement to raise between $4 million and $7.5 million through a combination of common share units and flow-through shares priced at $0.13 and $0.17 respectively. Each unit includes a common share and a warrant exercisable at $0.20 for 36 months, subject to delayed exercisability, an acceleration clause tied to share price performance, and potential finder compensation via cash and broker warrants.
The financing, offered under a listed issuer financing exemption in most Canadian provinces, is expected to close in late April 2026 subject to TSX Venture Exchange approval and may close in multiple tranches after the minimum is reached. Net proceeds are earmarked for barium contrast inventory, exploration and feasibility work at Frances Creek, U.S. iodine project development, sales and marketing of contrast products, FDA licensing, regulatory approvals for bulk sampling, and general corporate purposes, signalling a push to advance commercialization and regulatory milestones across Voyageur’s asset base.
The most recent analyst rating on (TSE:VM) stock is a Sell with a C$0.16 price target. To see the full list of analyst forecasts on Voyageur Pharmaceuticals stock, see the TSE:VM Stock Forecast page.
Spark’s Take on VM Stock
According to Spark, TipRanks’ AI Analyst, VM is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, large losses, and rising cash burn that implies funding/dilution risk), only partly offset by low leverage and positive equity. Technical indicators are broadly neutral and provide limited support, while valuation is constrained by negative earnings and no dividend yield.
To see Spark’s full report on VM stock, click here.
More about Voyageur Pharmaceuticals
Voyageur Pharmaceuticals is a Calgary-based Canadian developer of pharmaceutical-grade barium and iodine used in medical imaging contrast media. The company focuses on building a vertically integrated supply chain for contrast agents, with projects including the Frances Creek barium operation and a U.S. iodine development initiative targeting diagnostic imaging markets.
Average Trading Volume: 79,140
Technical Sentiment Signal: Sell
Current Market Cap: C$17.86M
See more data about VM stock on TipRanks’ Stock Analysis page.